Today: 29 April 2026
Browse Category

NYSE:CNC 4 October 2025 - 28 April 2026

UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Group shares rose about 4% Tuesday after Centene raised its profit forecast, fueling optimism that medical-cost pressures may be easing for large insurers. UnitedHealth last week lifted its 2026 profit outlook and reported a first-quarter medical care ratio of 83.9%. Centene’s medical loss ratio came in below analyst estimates. UnitedHealth’s Optum unit continues to face cost and contract challenges.
28 April 2026
·····
Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Molina Healthcare plunged 25.5% after forecasting 2026 profit far below estimates and announcing a 2027 exit from Medicare Part D. Centene guided profit above expectations but dropped 3.7%, while Cigna rose 2.6% on a strong quarter but flagged a softer 2026 outlook. XLV gained 1.8%. Hims fell 10% after the FDA warned against mass-marketing compounded obesity drugs.
7 February 2026
···
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Centene shares closed at $40.46 on December 11, up 4.6% after Baird raised its price target to $36 while keeping a Neutral rating. The stock remains 39% below its 52-week high. Uncertainty persists over expiring ACA premium subsidies, with no Senate deal reported as of December 11. Policy risk and Medicaid margins continue to weigh on investor sentiment.
12 December 2025
·
Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene shares jumped above $40 on December 11, 2025, after Baird raised its price target to $36 but kept a neutral rating. The stock closed at $40.73, up 5.3%, extending a rebound from a summer marked by guidance cuts and a rare loss. CNC now trades about 62% above its 52-week low but remains 39% below its February high. The price is at or above most analyst targets, with consensus ratings still cautious.
11 December 2025
·
Centene (CNC) Slides on ACA-Subsidy Uncertainty as Wellcare Expands in Texas and Ambetter Adds South Carolina Plans — Nov. 10, 2025

Centene (CNC) Slides on ACA-Subsidy Uncertainty as Wellcare Expands in Texas and Ambetter Adds South Carolina Plans — Nov. 10, 2025

Centene shares fell about 7% in premarket trading after President Trump called for ACA subsidies to be sent directly to consumers instead of insurers, pressuring managed-care stocks. Centene announced Wellcare will expand Medicare Advantage and Part D plans in 205 Texas counties for 2026, and Ambetter will launch statewide 2026 Marketplace plans in South Carolina. As of 14:48 UTC, CNC traded at $33.91.
10 November 2025
·
Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health reported Q3 2025 adjusted earnings of $6.03 per share, beating analyst estimates by over $1. Revenue reached $50.1 billion, up 12% year-over-year and ahead of forecasts. Shares jumped as much as 7% pre-market on Oct. 21 before settling near the prior close. The company reaffirmed its full-year outlook and kept costs slightly below expectations.
21 October 2025
····
Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

The S&P 500 and Dow closed at record highs Friday, with the Dow up 0.5% despite a third day of the U.S. government shutdown. The September jobs report was delayed, but traders expect a Fed rate cut in late October. Utilities and health insurers led gains, while tech stocks lagged. Palantir dropped 7.5% after a U.S. Army memo flagged security issues; Applied Materials fell 3% on China export curbs.
4 October 2025
····

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
Go toTop